ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in…
Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023 TEL AVIV, Israel, July 05, 2023…